title: [Characteristics of 11 patients with acute myeloid leukemia accompanied with karyotype aberration t(6;9)].
abstract: This study was aimed to investigate the characteristics of 11 patients with acute myeloid leukemia (AML) accompanying with karyotype t(6;9). The laboratorial and clinical data were analyzed retrospectively, including immunophenotype analysis and result analysis of real-time quantitative PCR detection. The results showed that a high prevalence of M2 was observed. Among 11 cases, 6 of M2, 2 of M4, 2 of M5 and 1 of MDS-RAEBT were found according to FAB criteria. Ten patients had high counts of peripheral white blood cells. Bone marrow dysplasia was seen in only 2 cases, and basophilia occurred in 4 cases. Six patients carried additional cytogenetic aberrations apart from t(6;9). Immunophenotypic analysis showed that all patients were positive for CD117, CD33, CD13, HLA-DR, CD38 and CD123. No NPM1 mutation was observed in all patients and a high level of WT1 was detected in all patients (7/7), out of 7 patients FLT3-ITD mutation was detected in only 3 patients. Follow-up details were available for 7 patients, one of whom died before chemotherapy, and the remaining 6 patients all had no response to IA or DA regimen. Among the 6 patients, 3 did not response to subsequently chemotherapy and all died from infections in a short period after diagnosis, the other 3 patients achieved a complete remission after alternative chemotherapy, but 2 relapsed in a short time and died. It is concluded that AML with cytogenetic aberration of t(6,9) is a distinct disease with a very poor prognosis. The first line chemotherapy such as IA or DA regimen is not effective to such patients, and the effective treatment needs further study.
authors.affiliation: Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China. laiyueyun1008@yahoo.com.cn
authors.forename: Yue-Yun
authors.initials: YY
authors.lastname: Lai
authors.forename: Ye
authors.initials: Y
authors.lastname: Li
authors.forename: Yan
authors.initials: Y
authors.lastname: Shi
authors.forename: Hui
authors.initials: H
authors.lastname: Dang
authors.forename: Qi
authors.initials: Q
authors.lastname: He
authors.forename: Lin
authors.initials: L
authors.lastname: Feng
authors.forename: Zheng
authors.initials: Z
authors.lastname: Wang
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Wang
authors.forename: Na
authors.initials: N
authors.lastname: Li
authors.forename: Qing
authors.initials: Q
authors.lastname: Liu
authors.forename: Yan-Rong
authors.initials: YR
authors.lastname: Liu
authors.forename: Ya-Zhen
authors.initials: YZ
authors.lastname: Qin
authors.forename: Hong-Xia
authors.initials: HX
authors.lastname: Shi
authors.forename: Xaio-Jun
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000328:Adult; D002896:Chromosomes, Human, Pair 6 / Q000235:genetics; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics; D005260:Female; D006801:Humans; D059785:Karyotype; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D000090243:Nucleophosmin; D011379:Prognosis; D012189:Retrospective Studies; D014178:Translocation, Genetic; D055815:Young Adult